RxDoctor Payments Data

Brittany Chapman, MD

Neurology · Louisville, KYNPI 1417119082

Payments from drug & device makers

$8,839in general payments, 2019–2025

Across 225 payments — averaging $39.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$4K
  • Neuropace, Inc.$2K
  • UCB, Inc.$465
  • Sunovion Pharmaceuticals Inc.$376
  • AbbVie$256
  • SK Life Science, Inc.$199
  • plus $2K from 34 others

What the payments were for

  • Speaking & faculty fees$130%
  • Travel & lodging$2,49628%
  • Food & beverage$6,33072%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,839 in reported general payments places this provider in the 60th percentile of 210 neurology providers in Kentucky.

See all neurology providers in Kentucky

Medicare billing

Part B allowed, 2024
$19,253
Medicare patients
128
Services billed
220

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BriviactBrivaracetam23$38,345
VimpatLacosamide19$18,221
DilantinPhenytoin Sodium Extended22$7,537
Divalproex Sodium41$6,988
Clobazam28$3,770
Lacosamide38$3,434
Carbamazepine11$2,932
Levetiracetam ErLevetiracetam20$2,828
Levetiracetam76$2,222
Carbamazepine ErCarbamazepine16$2,128
Oxcarbazepine16$1,521
Lamotrigine67$1,033
Topiramate45$632
Carbidopa-LevodopaCarbidopa/Levodopa24$520
Phenobarbital12$459

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Vimpat$465$56,56642 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 210 neurology providers in Kentucky.

Other neurology in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →